Medicare beneficiaries with Part D coverage will gain access to certain GLP-1 drugs for weight loss starting July 1, 2026, but the list of eligible medications is narrower than many expect. Wegovy and Zepbound qualify because each carries a separate FDA-approved indication beyond weight management. Ozempic, despite containing the same active ingredient as Wegovy, does not meet the coverage criteria when prescribed solely for weight loss.
How the July 2026 GLP-1 coverage rules separate Wegovy from Ozempic
The distinction between covered and excluded drugs traces back to a statutory exclusion baked into the Social Security Act. Under Section 1927(d)(2), Medicaid may exclude agents when used for anorexia, weight loss, or weight gain. Part D’s own definition of covered drugs incorporates those same exclusion categories, which means any medication prescribed purely for weight loss falls outside the basic benefit unless a different approved use applies.
That legal architecture is what creates the split between Wegovy and Ozempic. Both contain semaglutide, but Wegovy holds an FDA indication to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight. The clinical foundation for that label came from the SELECT trial, published in The New England Journal of Medicine, which showed that semaglutide 2.4 mg reduced major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity without diabetes. Ozempic, by contrast, is labeled for type 2 diabetes management. When a physician writes an Ozempic prescription for weight loss alone, no secondary indication exists to override the statutory exclusion.
Zepbound enters through a different door entirely. The FDA approved tirzepatide, marketed as Zepbound, as the first medication indicated for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. That sleep apnea indication, not weight loss, is what makes Zepbound coverable under the basic Part D benefit. CMS operational guidance to Part D plan sponsors explicitly names both Wegovy for reducing major adverse cardiovascular events risk and Zepbound for moderate-to-severe obstructive sleep apnea as examples of drugs coverable under the basic Medicare Part D benefit.
Stricter plan verification could push prescribing toward diabetes-labeled drugs
A practical consequence of these rules is that Part D plans will need to verify which indication supports each prescription before approving coverage. Plans that enforce tight indication checks for Wegovy and Zepbound could inadvertently push some beneficiaries and their physicians toward diabetes-labeled semaglutide products. If a beneficiary lacks a qualifying cardiovascular diagnosis for Wegovy or a documented sleep apnea diagnosis for Zepbound, the path of least resistance could be an Ozempic prescription written under the diabetes indication, assuming the patient also has type 2 diabetes.
That dynamic raises a real tension. Beneficiaries who want GLP-1 treatment primarily for weight management may face different coverage outcomes depending on their comorbidities and how closely plans scrutinize documentation. Physicians, meanwhile, must balance clinical judgment with the administrative realities of prior authorization, chart reviews, and potential audits. In some cases, the same patient characteristics that clinically justify a GLP-1 may not align neatly with the narrow non–weight loss indications that unlock Part D coverage.
Part D sponsors already use tools such as step therapy, quantity limits, and prior authorization to manage expensive drugs, and the Medicare program allows plans to structure formulary management and utilization review around covered indications. For Wegovy and Zepbound, that is likely to mean diagnosis codes, evidence of cardiovascular disease or obstructive sleep apnea, and possibly specialist involvement before a claim is approved. By contrast, diabetes-labeled GLP-1 products may move through existing, more familiar pathways for type 2 diabetes treatment, even if weight loss is a major clinical goal.
The result could be divergent access patterns. Patients whose primary qualifying condition is cardiovascular disease or sleep apnea may be steered toward Wegovy or Zepbound, while those with diabetes may be more commonly treated with Ozempic or similar agents. Patients without any qualifying non–weight loss indication may find that none of these drugs are covered for them under Part D, underscoring how tightly the benefit is bound to statutory language rather than to broader public health goals around obesity.
What beneficiaries and prescribers should watch in 2026
As the July 2026 coverage start date approaches, beneficiaries and clinicians will need to pay attention to how individual plans implement these federal parameters. CMS has told plan sponsors, through its GLP-1 bridge guidance, that Wegovy and Zepbound can be covered when used for their non–weight loss indications, but plans retain latitude in how they design utilization controls and tier placement. Differences in copays, preferred status, and prior authorization criteria could significantly affect out-of-pocket costs and access.
Beneficiaries considering GLP-1 therapy should review their plan’s formulary, look for any notes about cardiovascular or sleep apnea indications, and discuss with their clinicians whether their medical history aligns with those label requirements. Prescribers, for their part, may need to document diagnoses more explicitly and ensure that prescriptions clearly reflect the indication that supports Part D coverage. In a landscape where the same molecule can be covered or excluded based solely on the labeled use, careful navigation of the rules will be as important as the choice of drug itself.
